The worldwide chronic myelomonocytic leukemia (CMML) treatment market is undergoing a period of rapid growth. This growth can be attributed to several factors, including the rising incidence of CMML, advancements in treatment, and increasing awareness about the disease. The market is marked by a varied range of treatments available, including targe